Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and what-not has, of course, returned. This leaves us with little choice but to fire up the coffee kettle and quaff a few cups of stimulation. Our choice today is coconut, for those tracking this sort of behavior. Feel free to join us. Meanwhile, here are some tidbits to help you along as the journey begins. Hope you have a smashing day and please do keep in touch …

AbbVie (ABBV) was reprimanded by the Food and Drug Administration for sloppy procedures when reviewing complaints of deaths that were reported in connection with three of its medicines, STAT reports. Following an inspection at an Illinois facility late last year, FDA examiners found the company failed to “thoroughly investigate” complaints over certain syringe kits for one medication that were associated with deaths, and also neglected to properly include historical complaint information for sorting through new reports that cited deaths for at least two other products.


A group of Takeda (TKPYY) Pharmaceutical shareholders is building support to block the $62 billion acquisition of Shire (SHPG) at an extraordinary general meeting, Reuters says. The 130-member group, which was formed by ex-Takeda employees holding 1 percent of Takeda shares, needs the support of a third of shareholders and is targeting domestic retail investors and overseas institutional investors, who own 25 percent and 35 percent of Takeda stock, respectively. The group includes members of the founding Takeda family, which owns about 10 percent of Takeda shares.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!